Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor ...

In a report released on March 28, Francois Brisebois from Oppenheimer maintained a Buy rating on Sensei Biotherapeutics (SNSE – Research ...

SNSE opened at $0.51 on Friday. Sensei Biotherapeutics has a 12-month low of $0.38 and a 12-month high of $1.94. The stock has a 50-day moving average price of $0.47 and a 200-day moving average ...

Sensei Biotherapeutics (NASDAQ:SNSE – Free Report) had its target price boosted by Oppenheimer from $3.50 to $4.00 in a research report report published on Friday morning,Benzinga reports.

Sensei Biotherapeutics' solnerstotug shows a 14% ORR in PD-(L)1 resistant tumors and remains well tolerated in early trial data from its Phase 1/2 study.

BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation ...

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...

Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) shares started out sharply higher Friday. The Boston-based clinical stage biotechnology company focused on the discovery and development of next-generation ...

BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation ...

Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical-stage biotechnology company developing next-generation immunotherapies for cancer. Through its TMAbTM (Tumor Microenvironment Activated ...

“Checkpoint inhibitor resistance remains a significant challenge for patients with advanced cancer, with limited treatment options beyond chemotherapy or clinical trials,” said Ron Weitzman, M.D., ...